Related | Appendix A. VTE Risk Assessment Medical (Padua)
Venous Thromboembolism Prophylaxis – Adult – Inpatient/Ambulatory
Appendix A. VTE Prophylaxis in Medical Patients
Modified Padua Risk Assessment Model
Risk Factor Points
Critically Ill 4
Inflammatory Bowel Disease 4
Admission for trauma (injured patient with fracture) 4
Active COVID-19 infection 4
Active Cancer 3
Previous VTE 3
Reduced Mobility 3
Thrombophilic Condition 3
Recent (< 1month) Trauma/Surgery 2
Age ≥ 70 years 1
Heart or Respiratory Failure 1
Acute Myocardial Infarction or Ischemic Stroke 1
Acute Infection or Rheumatologic Disorder 1
BMI ≥ 30 1
Ongoing Hormonal Treatment 1
Total Points
Low VTE Risk – no prophylaxis needed < 4
High VTE Risk – prophylaxis recommended > 4
VTE Prophylaxis Regimens for High VTE Risk Medical Patients
Patient
Population
VTE Prophylaxis Regimens
Preferred Option Alternative Option
High VTE Risk Enoxaparin 40 mg SQ every 24 hrsa Heparin 5000 units SQ every 8-12 hrsa
Trauma/Injury with
fracture
Enoxaparin 30 mg SQ every 12 hrsa Enoxaparin 0.5 mg/kg every 12 hrs
Heparin 5000 units SQ every 8-12 hrsc
Renal failure
(CrCl < 30 mL/min)*
*Not on renal
replacement therapy
Heparin 5000 units SQ every 8-12 hrsa Enoxaparin 30 mg SQ every 24 hrsb
Obesity Class 3
(BMI > 40 kg/M2)
Enoxaparin 40 mg SQ every 12 hrsb Heparin 5000 units SQ every 8 hrsb
Low body weight
(weight < 50 kg)
Heparin 5000 units SQ every 8-12 hrsa Enoxaparin 30 mg SQ every 24 hrsc
High Bleeding Risk Intermittent pneumatic compression
devices (IPC)a
Graduated compression stockings
(GCS) or Venous foot pumps (VFP)c
a: UW Health GRADE Moderate quality evidence, strong recommendation
b: UW Health GRADE Low quality evidence, strong recommendation
c: UW Health GRADE Low quality evidence, weak/conditional recommendation
Copyright © 2023 University of Wisconsin Hospitals and Clinics Authority. All Rights Reserved. Printed with Permission.
Contact: CCKM@uwhealth.org Last Revised: 03/2023
Effective 3/16/2023. Contact CCKM@uwhealth.org for previous versions